NASDAQ:KYMR Kymera Therapeutics (KYMR) Stock Price, News & Analysis $48.76 +0.39 (+0.81%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Kymera Therapeutics Stock (NASDAQ:KYMR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Kymera Therapeutics alerts:Sign Up Key Stats Today's Range$47.52▼$49.3350-Day Range$42.21▼$52.4052-Week Range$9.60▼$53.27Volume561,213 shsAverage Volume603,810 shsMarket Capitalization$2.99 billionP/E RatioN/ADividend YieldN/APrice Target$49.00Consensus RatingModerate Buy Company OverviewKymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Kymera Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks28th Percentile Overall ScoreKYMR MarketRank™: Kymera Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 856th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingKymera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 8 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageKymera Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Kymera Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kymera Therapeutics are expected to decrease in the coming year, from ($2.85) to ($3.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kymera Therapeutics is -20.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kymera Therapeutics is -20.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKymera Therapeutics has a P/B Ratio of 6.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Kymera Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.36% of the outstanding shares of Kymera Therapeutics have been sold short.Short Interest Ratio / Days to CoverKymera Therapeutics has a short interest ratio ("days to cover") of 17.5, which indicates bearish sentiment.Change versus previous monthShort interest in Kymera Therapeutics has recently decreased by 7.17%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKymera Therapeutics does not currently pay a dividend.Dividend GrowthKymera Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.36% of the outstanding shares of Kymera Therapeutics have been sold short.Short Interest Ratio / Days to CoverKymera Therapeutics has a short interest ratio ("days to cover") of 17.5, which indicates bearish sentiment.Change versus previous monthShort interest in Kymera Therapeutics has recently decreased by 7.17%, indicating that investor sentiment is improving significantly. News and Social Media3.1 / 5News Sentiment0.55 News SentimentKymera Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Kymera Therapeutics this week, compared to 4 articles on an average week.MarketBeat Follows2 people have added Kymera Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Kymera Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $897,280.00 in company stock.Percentage Held by Insiders15.82% of the stock of Kymera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Kymera Therapeutics' insider trading history. Receive KYMR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KYMR Stock News HeadlinesKymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31October 23 at 7:15 AM | globenewswire.comKymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 SymposiumOctober 23 at 7:00 AM | globenewswire.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)Kymera Therapeutics, Inc. (NASDAQ:KYMR) Short Interest UpdateOctober 18, 2024 | americanbankingnews.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $49.00 Consensus Target Price from AnalystsOctober 18, 2024 | americanbankingnews.comKymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 DegraderOctober 9, 2024 | globenewswire.comOppenheimer Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)September 28, 2024 | markets.businessinsider.comKymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV CongressSeptember 25, 2024 | globenewswire.comSee More Headlines KYMR Stock Analysis - Frequently Asked Questions How have KYMR shares performed this year? Kymera Therapeutics' stock was trading at $25.46 on January 1st, 2024. Since then, KYMR shares have increased by 91.5% and is now trading at $48.76. View the best growth stocks for 2024 here. How were Kymera Therapeutics' earnings last quarter? Kymera Therapeutics, Inc. (NASDAQ:KYMR) posted its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.58) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.10. The company's revenue for the quarter was up 55.2% compared to the same quarter last year. When did Kymera Therapeutics IPO? Kymera Therapeutics (KYMR) raised $126 million in an initial public offering on Friday, August 21st 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities acted as the underwriters for the IPO. Who are Kymera Therapeutics' major shareholders? Kymera Therapeutics' top institutional investors include Handelsbanken Fonder AB (0.03%), SG Americas Securities LLC (0.02%), Exchange Traded Concepts LLC (0.01%) and Mirae Asset Global Investments Co. Ltd.. Insiders that own company stock include Venture Fund X LP Atlas, Bvf Partners L P/Il, Bruce Booth, Bruce N Jacobs, Jared Gollob, Ellen Chiniara, Joanna Horobin, Jeffrey W Albers and Nello Mainolfi. View institutional ownership trends. How do I buy shares of Kymera Therapeutics? Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Kymera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kymera Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and First Solar (FSLR). Company Calendar Last Earnings8/07/2024Today10/23/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KYMR CUSIPN/A CIK1815442 Webwww.kymeratx.com Phone857-285-5300FaxN/AEmployees170Year FoundedN/APrice Target and Rating Average Stock Price Target$49.00 High Stock Price Target$65.00 Low Stock Price Target$30.00 Potential Upside/Downside+0.5%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-146,960,000.00 Net Margins-178.27% Pretax Margin-178.27% Return on Equity-28.88% Return on Assets-22.37% Debt Debt-to-Equity RatioN/A Current Ratio8.45 Quick Ratio8.45 Sales & Book Value Annual Sales$88.55 million Price / Sales33.79 Cash FlowN/A Price / Cash FlowN/A Book Value$7.12 per share Price / Book6.85Miscellaneous Outstanding Shares61,358,000Free Float51,984,000Market Cap$2.99 billion OptionableOptionable Beta2.21 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report This page (NASDAQ:KYMR) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.